|
Translating Epoetin Research Into Practice: The Role Of Government And The Use Of Scientific Evidence
Dennis Cotter,
Mae Thamer,
Krishnan Narasimhan,
Yi Zhang and
Kim Bullock
Spending for epoetin is Medicare’s single largest drug expenditure. We chronicle the evolution of epoetin policy based on a lack of well-designed post–Food and Drug Administration approval studies demonstrating clinical benefit; congressional/federal agency reliance on clinical practice guidelines that might have misinterpreted evidence supporting causality; and the premature translation of research into practice and policy. Were the right choices made? Epoetin showcases the risk and benefit conundrum created when evidentiary standards are relaxed. Our review concludes with broad-based policy recommendations for the newly implemented Medicare Part D program.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
A. K. Singh
Anemia of Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol.,
January 1, 2008;
3(1):
3 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Thamer, Y. Zhang, J. Kaufman, D. Cotter, F. Dong, and M. A. Hernan
Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis
JAMA,
April 18, 2007;
297(15):
1667 - 1674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Luft
Universal Health Care Coverage: A Potential Hybrid Solution
JAMA,
March 14, 2007;
297(10):
1115 - 1118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shaldon
Does erythropoetin improve survival in ESRD haemodialysis patients?
Nephrol. Dial. Transplant.,
March 1, 2007;
22(3):
962 - 962.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shaldon
The use of IV iron in the treatment of anaemia of ESRD patients on maintenance haemodialysis: an historical and personal view
Nephrol. Dial. Transplant.,
January 1, 2007;
22(1):
23 - 25.
[Full Text]
[PDF]
|
|
|
|
